Loading…
CIK 0001910456 • 7 13F filings • May 15, 2025 – Aug 13, 2026
Import this data to Google Sheets with:
=jivedata("lynx1-capital-management-lp","13f")Uses this filer's slug. Install the Jive Data add-on first; the second argument is "13f".
Past 5 quarters
| % of Portfolio | |||||
|---|---|---|---|---|---|
| ABSCI CORPORATION | COM | $246K | 0.0% | 21,245 SH | New |
| AGIOS PHARMACEUTICALS INC | COM | $126.5M | 14.6% | 3,408,937 SH | New |
| AVALO THERAPEUTICS INC | COM NEW | $187K | 0.0% | 10,100 SH | New |
| BOLT BIOTHERAPEUTICS INC | COM NEW | $119K | 0.0% | 30,800 SH | New |
| C4 THERAPEUTICS INC | COM STK | $34.2M | 4.0%Prev: 2.9% | 7,326,691 SH | Increased+228,558 SH |
| CG ONCOLOGY INC | COM | $2.2M | 0.3% | 31,391 SH | New |
| CULLINAN THERAPEUTICS INC | COM | $163.2M | 18.9%Prev: 9.6% | 8,963,500 SH | Increased+4,562,658 SH |
| DENALI THERAPEUTICS INC | COM | $300K | 0.0% | 11,658 SH | New |
| ENTRADA THERAPEUTICS INC | COM | $1.3M | 0.2% | 178,606 SH | New |
| EUPRAXIA PHARMACEUTICALS INC | COM | $66K | 0.0% | 10,000 SH | New |
| FOGHORN THERAPEUTICS INC | COM | $301K | 0.0% | 61,588 SH | New |
| GH RESEARCH PLC | ORDINARY SHARES | $356.5M | 41.2%Prev: 23.8% | 13,263,288 SH | Increased+6,516,337 SH |
| IMMATICS N.V | SHS | $235K | 0.0% | 23,236 SH | New |
| INHIBIKASE THERAPEUTICS INC | COM NEW | $41K | 0.0% | 20,000 SH | New |
| KORRO BIO INC | COM | $20.3M | 2.3% | 1,538,296 SH | New |
| NEUPHORIA THERAPEUTICS INC | COM | $3.8M | 0.4%Prev: 0.1% | 875,328 SH | Increased+829,522 SH |
| NUVATION BIO INC | COM CL A | $91K | 0.0% | 16,029 SH | New |
| PASSAGE BIO INC | COM NEW | $3.3M | 0.4% | 673,759 SH | New |
| PLIANT THERAPEUTICS INC | COM | $2.0M | 0.2% | 1,798,070 SH | New |
| PRECISION BIOSCIENCES INC | COM NEW | $7.5M | 0.9%Prev: 1.3% | 950,466 SH | Increased-85,585 SH |
| PROQR THRAPEUTICS N V | SHS EURO | $970K | 0.1% | 521,413 SH | New |
| STOKE THERAPEUTICS INC | COM | $132.1M | 15.3%Prev: 17.7% | 4,038,404 SH | Increased-1,366,270 SH |
| TRAWS PHARMA INC | COM NEW | $472K | 0.1% | 559,470 SH | New |
| TSCAN THERAPEUTICS INC | COM | $7.9M | 0.9%Prev: 3.3% | 8,019,148 SH | Decreased+161,801 SH |
| VYNE THERAPEUTICS INC | COM | $1.1M | 0.1% | 1,628,700 SH | New |
| WEREWOLF THERAPEUTICS INC | COM | $237K | 0.0% | 657,786 SH | New |
| XENCOR INC | COM | $293K | 0.0% | 18,194 SH | New |
| 13F-HR/A |
| 0001910456-26-000004 |
| $865.5M |
| View |
| Aug 14, 2025 | Q2 2025 | 13F-HR | 0001085146-25-005127 | $346.2M | View |
| May 4, 2026 | Q1 2026 | 13F-HR | 0001910456-26-000002 | $632.7M | View |
| May 15, 2025 | Q1 2025 | 13F-HR | 0001892688-25-000120 | $279.2M | View |